Cargando…

Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

Detalles Bibliográficos
Autores principales:	Jones, Jefferson M., Fleming-Dutra, Katherine E., Prill, Mila M., Roper, Lauren E., Brooks, Oliver, Sánchez, Pablo J., Kotton, Camille N., Mahon, Barbara E., Meyer, Sarah, Long, Sarah S., McMorrow, Meredith L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Centers for Disease Control and Prevention 2023
Materias:	Full Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468217/ https://www.ncbi.nlm.nih.gov/pubmed/37616235 http://dx.doi.org/10.15585/mmwr.mm7234a4

Ejemplares similares

Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
por: Fleming-Dutra, Katherine E., et al.
Publicado: (2023)

Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
por: Melgar, Michael, et al.
Publicado: (2023)

Seasonality of Respiratory Syncytial Virus — United States, 2017–2023
por: Hamid, Sarah, et al.
Publicado: (2023)

Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023
por: Regan, Joanna J., et al.
Publicado: (2023)

Nirsevimab brings breakthrough in the prevention of respiratory syncytial virus infection in infants – Importance of design
por: Zhaori, Getu
Publicado: (2023)

Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022
por: Rosenblum, Hannah G., et al.
Publicado: (2022)

Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection
por: Brady, Tyler, et al.
Publicado: (2023)

The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021
por: Mbaeyi, Sarah, et al.
Publicado: (2021)

Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023
por: Kobayashi, Miwako, et al.
Publicado: (2023)

Tick-Borne Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023
por: Hills, Susan L., et al.
Publicado: (2023)

The Laboratory Advisory Committee
Publicado: (1968)

Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 years — United States, July 2022
por: Twentyman, Evelyn, et al.
Publicado: (2022)

Recommendations of the Advisory Committee on Immunization Practices for Use of Cholera Vaccine
por: Wong, Karen K., et al.
Publicado: (2017)

Leicester Health Advisory Committee
Publicado: (1918)

Controlled Substance Advisory Committee
Publicado: (2022)

Report to the Committee of Council by the CERN History Advisory Committee
Publicado: (1985)

Meeting on the AEC Nuclear Cross Sections Advisory Committee
por: Chrien, R E
Publicado: (1972)

Meeting on the AEC Nuclear Cross Sections Advisory Committee
por: Jackson, H E
Publicado: (1972)

Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
por: Anderson, Tara C., et al.
Publicado: (2022)

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2023
por: Murthy, Neil, et al.
Publicado: (2023)

Respiratory syncytial virus‐associated deaths in the United States according to death certificate data, 2005 to 2016
por: Prill, Mila M., et al.
Publicado: (2021)

Standing Advisory Committee's new role
Publicado: (1983)

Standing Advisory Committee on Audits (SACA)
Publicado: (2015)

Report on CERN Staff by the Advisory Committee
Publicado: (1955)

LHCP International Advisory Committee report
por: Bose, Tulika
Publicado: (2022)

Organizing Committee and International Advisory Board
Publicado: (2012)

Adverse Report of the Local Advisory Committee
Publicado: (1921)

A Typology of Scientific Advisory Committees
por: Groux, Gaëlle M. N., et al.
Publicado: (2018)

Public Policy Advisory Committee Perspective
por: Harootyan, Linda
Publicado: (2020)

Respiratory Syncytial Virus Activity — United States, July 2011–January 2013
por: Haynes, Amber K., et al.
Publicado: (2013)

Inequalities in Health Impact of Alternative Reimbursement Pathways for Nirsevimab in the United States
por: Gomez, Gabriela B, et al.
Publicado: (2022)

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2023
por: Wodi, A. Patricia, et al.
Publicado: (2023)

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023–24 Influenza Season
por: Grohskopf, Lisa A., et al.
Publicado: (2023)

Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study
por: Shoukat, Affan, et al.
Publicado: (2023)

Respiratory Syncytial Virus — United States, July 2012–June 2014
por: Haynes, Amber K., et al.
Publicado: (2014)

The role of the Asia-Pacific advisory committee on influenza
por: Tam, John S, et al.
Publicado: (2004)

Introducing the 2023 JACS Au Early Career Advisory Board
Publicado: (2023)

Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
por: Ahani, Bahar, et al.
Publicado: (2023)

94. Pooled analysis of nirsevimab resistance through 150 days post dose in preterm and term infants
por: Abram, Michael E, et al.
Publicado: (2022)

1633. Willingness to receive maternal RSV vaccine and infant monoclonal RSV antibody
por: Gidengil, Courtney, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gs7oc47qm3m9b9bdbir8iutvqd